Canaccord Genuity Starts Blueprint Medicines (BPMC) at Buy
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Canaccord Genuity initiated coverage on Blueprint Medicines (NASDAQ: BPMC) with a Buy rating and a price target of $26.00.
Shares of Blueprint Medicines closed at $21.95 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- iRhythm Technologies (IRTC) Prices Larger Common Stock IPO at $17/Share, Above Expected Range
- Oppenheimer Raises Price Target on Microsoft (MSFT) to $65 Following 1Q Beat
- UPDATE: Seaport Global Securities Starts Union Pacific (UNP) at Buy
Create E-mail Alert Related CategoriesNew Coverage
Related EntitiesCanaccord Genuity
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!